News from abbvie A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 25, 2021, 08:00 ET Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia

Allergan, an AbbVie (NYSE: ABBV) company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for...

Feb 24, 2021, 19:14 ET HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to ...

Feb 23, 2021, 08:30 ET New REFRESH® DIGITAL Lubricant Eye Drops Tackle Eye Dryness Due to Everyday Screen Use

From scrolling through social media feeds, to video conferences for work and school, to relaxing with television and video games, Americans are...

Feb 22, 2021, 08:45 ET Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients

AbbVie (NYSE: ABBV) today announced that upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and ...

Feb 19, 2021, 09:15 ET AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation

AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce settlement agreements to fully resolve all outstanding litigation, including the...

Feb 19, 2021, 08:00 ET AbbVie to Present at the Cowen 41st Annual Health Care Conference

AbbVie (NYSE: ABBV) will participate in the Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021. Michael Severino, M.D., vice...

Feb 18, 2021, 10:58 ET AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. The cash dividend is payable May 14,...

Feb 12, 2021, 08:00 ET AbbVie to Present at the 10th Annual SVB Leerink Global Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26. Michael Severino, M.D., vice ...

Feb 10, 2021, 08:15 ET AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products

AbbVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they...

Feb 10, 2021, 08:00 ET BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition

Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX® for the treatment of...

Feb 03, 2021, 07:38 ET AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results

AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. "We successfully completed the...

Jan 26, 2021, 08:45 ET CoolSculpting® by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting® Elite

Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of CoolSculpting® Elite, its next generation fat reduction system...

Jan 25, 2021, 11:30 ET European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis

AbbVie (NYSE: ABBV), today announced that the European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an oral, once daily selective and ...

Jan 15, 2021, 09:00 ET Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference

Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurotoxins...

Jan 12, 2021, 16:05 ET Allergan Aesthetics Enters Into Option to Acquire Cypris Medical

Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into a warrant agreement with Cypris Medical, a privately...

Jan 12, 2021, 08:00 ET AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens....

Jan 07, 2021, 08:45 ET Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease

AbbVie (NYSE: ABBV) today announced positive results from two Phase 3 induction studies, ADVANCE and MOTIVATE, showing both doses of risankizumab...

Jan 06, 2021, 08:00 ET AbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Members of AbbVie's executive ...

Jan 05, 2021, 08:48 ET Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients

AbbVie (NYSE: ABBV) today announced positive top-line results from two Phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 and...

Dec 23, 2020, 07:30 ET IMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström's Macroglobulinemia (WM)

AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) approved the update of the IMBRUVICA® (ibrutinib) Prescribing...

Dec 14, 2020, 11:54 ET AbbVie Apresenta Novos Dados de VENCLEXTA® (venetoclax) para Tratamento com Duração Fixa de Leucemia Linfocitica Crônica (LLC)

A AbbVie (NYSE: ABBV) anunciou resultados atualizados dos estudos Fase 3 MURANO e CLL14 que avaliaram o tratamento com duração fixa de combinações de ...

Dec 11, 2020, 07:32 ET CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the...

Dec 10, 2020, 08:45 ET RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis

AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib (30 mg, once daily) achieved...

Dec 09, 2020, 11:25 ET AbbVie Announces Partners in $50 Million Program to Promote Health and Education Equity in Underserved Black Communities

AbbVie, a research-based global biopharmaceutical company, is investing $50 million in a five-year program to support underserved Black communities...

Dec 09, 2020, 08:45 ET Upadacitinib (RINVOQ™) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis

AbbVie (NYSE: ABBV) today announced positive results from the Phase 3 induction study, U-ACHIEVE, which showed upadacitinib (45 mg, once daily) met...